The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The partnership also sets the stage for broader collaboration on rare disease treatments
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Subscribe To Our Newsletter & Stay Updated
